Amgen resumes cancer trial;
> Amgen and Takeda say that they will resume a late-stage lung cancer trial for motesanib, but restrict it to patients with non-squamous cell type cancer.
Amgen today announced that it has licensed a clinical stage molecule for the treatment of chronic and neuropathic pain to Ortho-McNeil-Janssen Pharmaceuticals, Inc., a Johnson & Johnson company.